ERBB2 and breast carcinoma: The most prominent therapeutic monoclonal antibody is Herceptin® (trastuzumab) which is indicated for breast cancers involving the upregulation of HER2, a receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR)/HER family [21].